Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial

Trial Profile

Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Micafungin (Primary)
  • Indications Candidiasis; Nosocomial infections; Sepsis
  • Focus Therapeutic Use
  • Acronyms EMPIRICUS
  • Most Recent Events

    • 05 Oct 2016 Primary endpoint has not been met, (survival to 28 days without proven fungal infection (a fungal infection occurring within 48 hours after inclusion will be considered available for inclusion)), according to the results published.
    • 05 Oct 2016 Results (n=260) published in the JAMA: the Journal of the American Medical Association.
    • 23 Mar 2015 Status changed from recruiting to completed as reported by Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top